Drugs moving into the clinic: 11

By Mike Nagle

- Last updated on GMT

The eleventh in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.

Sponsor NameIndicationMechanism
Array BioPharma & AstraZenecaARRY-704 (AZD8330)Oncology - undisclosed but preclinical studies in melanoma, pancreatic, colon, lung, and breast cancersMEK inhibitor - MEK regulates cell proliferation and survival as part of the Ras/Raf/MEK/ERK pathway.
Poniard Pharmaceuticals Oral picoplatin Oncology - various solid tumours Cytotoxic platinum compound - causes cell death by binding to DNA and interfering with DNA replication and transcription N.B. other Phase I & II clinical trials for intravenous formulation
Kalypsys KD7040 Neuropathic pain Topical inducible nitric oxide synthase (iNOS) inhibitor
Hadasit Bio-Holdings & Verto Lupusorb Autoimmune - Lupus Device with specific peptide (VRT101 - from C terminal of laminin) to remove disease-causing auto-antibodies from the blood during plasmapheresis. N.B. Combined Phase I/II trial
Addex Pharmaceuticals ADX48621 CNS - primarily depression but also potentially generalised anxiety disorder and inflammatory pain Negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5)

Related topics: Preclinical Research

Related news

Show more